

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number
WO 01/44212 A1

(51) International Patent Classification⁷: C07D 263/20,
A61K 31/495, A61P 31/04

(74) Agent: YANG, Lucy, X.; Intellectual Property Legal Ser-
vices, Pharmacia & Upjohn Company, 301 Henrietta Street,
Kalamazoo, MI 49001 (US).

(21) International Application Number: PCT/US00/32432

(22) International Filing Date: 6 December 2000 (06.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/170,675 14 December 1999 (14.12.1999) US

(71) Applicant (for all designated States except US): PHAR-
MACIA & UPJOHN COMPANY [US/US]; 301 Henri-
etta Street, Kalamazoo, MI 49001 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(72) Inventor; and

(75) Inventor/Applicant (for US only): HESTER, Jackson,
B., Jr. [US/US]; 9219 East ML Avenue, Galesburg, MI
49053 (US).

(54) Title: BENZOIC ACID ESTERS OF OXAZOLIDINONES HAVING A HYDROXYACETYLPYPERAZINE SUBSTITUENT



(I)

(57) Abstract: The present invention provides a compound of
formula (I) which have potent activities against gram positive
and gram-negative bacteria.



WO 01/44212 A1

BENZOIC ACID ESTERS OF OXAZOLIDINONES HAVING
A HYDROXYACETYLPIPERAZINE SUBSTITUENT

5 FIELD OF THE INVENTION

The present invention relates to novel benzoic acid esters of oxazolidinones having a hydroxyacetyl piperazine substituent and their preparations. These compounds have potent activities against gram positive and gram-negative bacteria.

10 BACKGROUND OF THE INVENTION

The oxazolidinone antibacterial agents are a novel synthetic class of antimicrobials with potent activity against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci, anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms
15 such as *Mycobacterium tuberculosis* and *Mycobacterium avium*.


However, oxazolidinones generally do not demonstrate an activity at a useful level against aerobic gram-negative organisms. Thus, the use of these oxazolidinone antibacterial agents is limited to infectious states due to gram-positive bacteria. Accordingly, it is among the objects of the present invention to provide pharmaceutical
20 compounds which have broader antibacterial activity including the activity against aerobic gram-negative organisms. We have now discovered that the oxazolidinones of the present invention increase the spectrum of activity to include gram-negative organisms such as *Haemophilus influenza* and *Moraxella catarrhalis*. In addition, the compounds of the present invention are excellent water soluble agents, which makes them particularly useful
25 for IV and oral administration for the treatment of microbial infections.

INFORMATION DISCLOSURE

U.S. Patent 5,652,238 discloses carboxylic and phosphate esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones.
30 PCT International Publication WO 98/54161 discloses oxazolidinone antibacterial agents having a thiocarbonyl functionality.

SUMMARY OF THE INVENTION


The present invention provides a compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein:

A is a structure i, ii, iii, or iv



5

W is

- a) $\text{NHC}(=\text{X})\text{R}_1$,
- b) $-\text{O}-\text{het}$, $-\text{S}-\text{het}$, or $-\text{NH}-\text{het}$; provided that when A is a structure iv, W is not the section b);


10 X is O, or S;

R_1 is

- (a) H,
- (b) NH_2 ,
- (c) $\text{NHC}_{1-4}\text{alkyl}$,
- 15 (d) $\text{C}_{1-4}\text{alkyl}$, optionally substituted by one or more F, Cl, or CN,
- (e) $\text{C}_{2-4}\text{alkenyl}$,
- (f) $\text{OC}_{1-4}\text{alkyl}$,
- (g) $\text{SC}_{1-4}\text{alkyl}$, or
- (h) $(\text{CH}_2)_n\text{C}_{3-6}\text{cycloalkyl}$;

20 R_2 and R_3 are independently H, F, Cl or $\text{C}_{1-2}\text{alkyl}$;

R_4 is positioned at either C-3 or C-4 and is:



R_5 is H, or CH_3 ;

R_6 is H, or $\text{C}_{1-4}\text{alkyl}$, optionally substituted by OH, SH, SCH_3 , NH_2 or $\text{NHC}(=\text{NH})\text{NH}_2$;

R₇ and R₈ are independently H, C₁₋₄alkyl, or R₇ and R₈ together with the nitrogen to which they are attached to form a saturated 5-, 6-, or 7-membered heterocyclic ring which may have additional heteroatoms selected from the group consisting of O, S(O)_n, or N-R₅; het is a C-linked five- (5) or six- (6) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring; at each occurrence, het is optionally substituted with one or more halo, OH, CF₃, OC₁₋₆alkyl, CN, C₁₋₆alkyl, S(=O)_iR⁹, C(=X)R¹⁰, OC(=O)R¹⁰, NHC(=O)R¹⁰, or NR¹⁰R¹⁰, oxo, or oxime; wherein R⁹ is C₁₋₆alkyl, aryl, or NR⁷R⁸; R¹⁰ is H, C₁₋₆alkyl, aryl, or NR⁷R⁸; n is 0, 1, or 2; and with the proviso that when X is O, R₄ is not the subsection (a).

In another aspect, the present invention also provides:

a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, a method for treating gram-positive microbial infections in humans or other warm-blooded animals by administering to the subject in need a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a method for treating gram-negative microbial infections in humans or other warm-blooded animals by administering to the subject in need a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

The invention also provides some novel intermediates and processes that are useful for preparing compounds of formula I.

DETAILED DESCRIPTION OF THE INVENTION

The following definitions are used, unless otherwise described.

The term alkyl, alkenyl, etc. refer to both straight and branched groups, but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to.

The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C_{i-j} indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus, for example, C₁₋₇ alkyl refers to alkyl of one to seven carbon atoms, inclusive.

Mammal refers to human or animals.

The compounds of the present invention are generally named according to the IUPAC or CAS nomenclature system. Abbreviations which are well known to one of ordinary skill in the art may be used (e.g. "Ph" for phenyl, "Me" for methyl, "Et" for ethyl, "O" for oxygen atom, "S" for sulfur atom, "N" for nitrogen atom, "h" for hour or hours and
5 "rt" for room temperature).

The term "het" refers to a C-linked five- (5) or six- (6) membered heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring.

Examples of "het" include pyridine, thiophene, furan, pyrazoline, pyrimidine, 2-
10 pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazinyl, 4-oxo-2-imidazolyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 4-oxo-2-oxazolyl, 5-oxazolyl, 1,2,3-oxathiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazole, 4-
15 isothiazole, 5-isothiazole, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-isopyrrolyl, 4-isopyrrolyl, 5-isopyrrolyl, 1,2,3-oxathiazole-1-oxide, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 5-oxo-1,2,4-oxadiazol-3-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 3-oxo-1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-5-yl, 2-oxo-1,3,4-thiadiazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3,4-tetrazol-5-yl, 5-oxazolyl, 3-isothiazolyl, 4-
20 isothiazolyl and 5-isothiazolyl, 1,3,4-oxadiazole, 4-oxo-2-thiazoliny, or 5-methyl-1,3,4-thiadiazol-2-yl, thiazolodione, 1,2,3,4-thiatriazole, or 1,2,4-dithiazolone.

At each occurrence, het may be substituted with one or more group as defined in the summary of the invention or in claims.

A specific value for het is isoxazol-3-yl, isoxazol-5-yl, 1,2,4-oxadiazol-3-yl,
25 isothiazol-3-yl, 1,2,4-thiadiazol-3-yl or 1,2,5-thiadiazol-3-yl.

Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.

Specifically, C₁₋₄ alkyl, can be an alkyl group having one to four carbon atoms such
30 as, for example, methyl, ethyl, propyl, butyl, and their isomeric forms thereof; C₂₋₄ alkenyl can be vinyl, propenyl, allyl, butenyl, and their isomeric forms thereof; C₃₋₆ cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and their isomeric forms thereof.

A specific value for A is structure ii as defined above.

A specific value for X is sulfur atom.

A specific value for X is oxygen atom.

A specific value for R₁ is C₁₋₄alkyl.

A more specific value for R₁ is ethyl.

5 A specific value for R₁ is cyclopropyl.

A specific value for R₁ is NH₂.

A specific value for R₂ and R₃ are independently H or F.


A specific value for R₂ and R₃ are that one of them is H, the other one is F.

A specific value for R₄ is -CH₂N(CH₃)₂.


10 A specific value for R₄ is 4-morpholinylmethyl.

A specific value for R₄ is 4-methyl-1-piperazinylmethyl.

A specific value is that R₄ is positioned at either C-3 or C-4. The positions C-3 and C-4 refer to the following positions respectfully:



15 The preferred compounds of the present invention are those wherein structure i, ii, or iii has an optical configuration below:



These absolute configurations are called (S)-configuration according to the Cahn-Ingold-Prelog nomenclature system.

20 Examples of the present invention are:

(1) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(dimethylamino)methyl]benzoic acid ester,

(2) (S)-N-[[3-[3-fluoro-4-[4-[(hydroxy acetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-[(dimethylamino)methyl]benzoic acid ester,

25 (3) (S)-N-[[3-[3-fluoro-4-[4-[(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-(morpholinomethyl)benzoic acid ester,

- (4) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-[(4-methyl-1-piperazinyl)methyl]benzoic acid ester,
- (5) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-[(diethylamino)methyl]benzoic acid ester,
- (6) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(diethylamino)methyl]benzoic acid ester,
- (7) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-(morpholinomethyl)benzoic acid ester,
- (8) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid ester,
- (9) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarbothioamide 4-[(dimethylamino)methyl]benzoic acid ester,
- (10) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thiourea 4-[(dimethylamino)methyl]benzoic acid ester,
- (11) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-(glycylamino)benzoic acid ester,
- (12) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarbothioamide 4-(glycylamino)benzoic acid ester, or
- (13) (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-(L-alanyl amino)benzoic acid ester.


The following Schemes describe the preparation of compounds of the present invention. All of the starting materials are prepared by procedures described in these schemes or by procedures that would be well known to one of ordinary skill in organic chemistry. The variables used in the Schemes are as defined below or as in the claims. The compounds of this invention can be prepared in accordance to one or more of the Schemes discussed below.

As shown in Scheme I, compound 1-a with an appropriate amino protecting group (P) is esterified with either 3- or 4-nitrobenzoyl chloride to provide compound 1-b. In this reaction a tertiary amine base such as triethylamine may be used to neutralize the hydrogen


chloride formed. Non-protic solvents such as CH_2Cl_2 or THF and temperatures in the range of 0-24°C are suitable for this reaction. Protecting groups (P) are chosen for their compatibility with the chemistry and functional groups of the molecules being synthesized. For the compounds synthesized in Examples 1-12 tert-butoxycarbonyl (Boc) is a suitable protecting group; however, depending on the chemistry and compounds desired other protecting groups may be employed. Synthesis of Compound 1-b wherein P is Boc is described in PCT International Publication WO 98/54161 and exemplified in Example 1 of the present invention. The nitro group of Compound 1-b is reduced to the amine to provide compound 1-c. This is conveniently accomplished by catalytic hydrogenation with a palladium catalyst in solvents such as MeOH, EtOH and CH_2Cl_2 at room temperature; however, other catalytic or chemical methods known to one skilled in the art can be employed if desired. Compound 1-c where R_5 is methyl can be obtained by alkylating the amine formed in this reaction. Acylating the aniline 1-c with an appropriately activated amino acid derivative provides 1-d. Example 11, Step 3 illustrates the use of an acid chloride and tertiary amine base for this reaction; however, condensing agents such as 1,1'-carbonyldiimidazole and 1,3-dicyclohexylcarbodiimide/1-hydroxybenzotriazole which are well known in the art of peptide chemistry can also be used for this reaction. In Schemes I, II and III when R_6 contains an OH or SH and when R_7 and or R_8 are hydrogen a protecting group (P') may be required. Example 11, Step 3 illustrates the use of 9-fluorenylmethoxycarbonyl (Fmoc) for protecting the amino group of glycine. Fmoc is stable to conditions suitable for removing Boc (Example 11, Step 4) but can be readily removed (piperidine in DMF) in the presence of a thioamide (Example 11, Step 6). The benzyloxycarbonyl can also be removed (HBr/HOAc) in the presence of a thioamide and is thus a suitable P' group. Compound 1-d is deprotected to provide 1-e. Acylating 1-e provides 1-f. Any additional protecting groups (P') can be then removed at this stage. Removal of the Boc protecting group from 1-d can be conveniently carried out with HCl in dioxane to give the hydrochloride salt of the amine. This salt can often be used directly in the subsequent acylation. Acylation of the amine or amine hydrochloride 1-e with dithioesters and a tertiary amine base to give thioamides is carried out in solvents such as CH_2Cl_2 , THF or preferably MeOH at temperatures in the range of 24-50°C. Preparations of other thiocarbonyl compounds can be prepared according to the procedures described in PCT International Publication WO 98/54161.

In Scheme II the intermediate alcohol 2-a is esterified with a 3- or 4-(1-chloroalkyl)benzoyl chloride and a tertiary amine base in an appropriate solvent such as CH_2Cl_2 at a temperature in the range of 0-40°C to give compound 2-b. Alkylation of an amine with 2-b provides compound 2-c. The reaction can be carried out in solvents such as acetone or CH_2Cl_2 with a catalytic amount of sodium iodide at a temperature ranging from ambient to the reflux temperature of the solvent. Deprotection of 2-c to provide 2-d, and the preparation of compounds 2-e are carried out by the same procedures described in Scheme I.


In Scheme III the alcohol intermediate 3-a is esterified with an appropriately

substituted benzoic acid () to provide compound 3-b. As described in Schemes I and II, the acid chlorides and a tertiary amine base can be used for this reaction. In addition this reaction can be carried out with reagent systems such as 1,3-dicyclohexylcarbodiimide and 4-dimethylaminopyridine or triphenylphosphine and diethyl azodicarboxylate. The remaining steps which lead to the compounds of formula I of the present invention are carried out by the same procedures described in Schemes I and II.


SCHEME I



SCHEME II



SCHEME III



5 The pharmaceutical compositions of this invention may be prepared by combining the compounds of Formula I of this invention with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipient employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier

10 can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and

15 emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.

Preferably, the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing effective or appropriate amounts of the active component, that is, the compounds of formula I according to this invention.

5 The quantity of active component, that is the compound of formula I according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.

10 In therapeutic use for treating, or combating, bacterial infections in warm-blooded animals, the compounds or pharmaceutical compositions thereof will be administered orally, topically, transdermally, and/or parenterally at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective. Generally, such antibacterially effective amount of dosage of active component will be in the range of about 0.1 to about 15 100, more preferably about 1.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased 20 during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.

The compounds of formula I according to this invention are administered 25 parenterally, i.e., by injection, for example, by intravenous injection or by other parenteral routes of administration. Pharmaceutical compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compound according to formula I as a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a buffer to provide a 30 suitably buffered isotonic solution, for example, having a pH of about 3.5-6. Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine to name but a few representative buffering agents. The compounds according to formula I generally will be

dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/ml to about 400 mg/ml of solution. The resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned antibacterially effective amount of dosage. The compounds of formula I

5 according to this invention are advantageously administered orally in solid and liquid dosage forms.

The oxazolidinone antibacterial agents of this invention have useful activity against a variety of organisms. The in vitro activity of compounds of this invention can be assessed by standard testing procedures such as the determination of minimum inhibitory

10 concentration (MIC) by agar dilution as described in "Approved Standard. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically", 3rd. ed., published 1993 by the National Committee for Clinical Laboratory Standards, Villanova, Pennsylvania, USA. The activity of compounds of this invention against *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococcus pneumoniae*, *Enterococcus faecalis*,

15 *Moraxella catarrhalis* and *H. influenzae* is shown in Table 1.

Antibacterial Activity Minimum Inhibitory Concentration ($\mu\text{g/mL}$)

Table 1

	SAUR. 9213	SEPI 30593	EFAE 12712	SPNE 9912	SPYO 152	HINF 30063	EFAE 9217	MCAT 30607
Ex- number	SAUR 9213 MIC	SEPI 30593 MIC	EFAE 12712 MIC	SPNE 9912 MIC	SPYO 152 MIC	HINF 30063 MIC	EFAE 9217 MIC	MCAT 30607 MIC
1	0.5	0.25	0.5	<0.06	<0.06	4	0.25	0.5
2	1	0.25	0.5	0.125	<0.06	8	0.5	0.5
3	4	2	2	0.5	0.5	64	2	4
4	8	2	2	0.5	0.5	64	2	4
5	2	2	2	0.25	0.25	32	1	2
6	2	1	1	0.25	0.125	16	1	2
7	2	2	2	0.5	0.25	64	1	4
8	2	1	1	0.125	0.125	16	1	1
9	0.5	0.125	0.5	<0.06	<0.06	8	0.5	0.5
10	4	0.5	0.5	0.125	<0.06	8	0.5	2


20

25

EXAMPLES


Example 1: (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(dimethylamino)methyl]benzoic acid ester (**7**)

5 **Step 1 :**




A stirred, ice cold mixture of **1** (PCT International Publication WO 98/54161) (20.0 g, 50.7 mmol), acetone (1500 mL) and saturated aqueous sodium bicarbonate (500 ml) is treated, during 20 min, with a solution of benzyloxycarbonyl chloride (9.5 ml, 60.8 mmol) in acetone (150 ml). The mixture is allowed to warm slowly to ambient temperature (24°C) and stand for 18 hours. It is extracted with Et₂O and the extract is washed with water and brine, dried (MgSO₄), and concentrated to give 25.4 g of the product **2**.


Step 2 :




15 A mixture of **2** (25.0 g, 46.1 mmol), MeOH (1700 ml) and 10% palladium - on - carbon catalyst (6.25 g) is hydrogenated at an initial pressure of 35 p.s.i. for 4 days. Additional catalyst (6.25 g) is added and the hydrogenation is continued for 1 day. The mixture is filtered and the filtrate is concentrated. Chromatography of the residue on silica gel with 2.5% MeOH-CH₂Cl₂ gave the product which is crystallized from acetone - CH₂Cl₂ to give 13.7 g of **3**.

Step 3:


A stirred mixture of **3** (5.70 g, 12.6 mmol) and triethylamine (2.99 ml, 21.4 mmol) in CH_2Cl_2 (76 ml) is treated at ambient temperature (24°C) with a solution of 4-(chloromethyl) benzoyl chloride (3.57 g, 18.9 mmol) in CH_2Cl_2 (32 ml) and kept at ambient temperatures for 4 days. It is washed with saturated aqueous NaHCO_3 , dried (MgSO_4) and concentrated. Chromatography of the residue on silica gel with 5% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ gave the product which is dissolved in CH_2Cl_2 (40 ml) and precipitated with hexane to give 5.37 g of **4**.

Step 4:

A stirred mixture of **4** (650 mg, 1.05 mmol), NaI (11 mg), 2M dimethylamine in MeOH (2.1 ml, 4.20 mmol) and acetone (14 ml) is kept at ambient temperature for 24 h, mixed with water (20 ml) and extracted with CH_2Cl_2 . The extracts are dried (MgSO_4) and concentrated. Chromatography of the residue on silica gel with 5% $\text{MeOH}/0.5\%$ $\text{NH}_4\text{OH}/\text{CH}_2\text{Cl}_2$ gave 559 mg of **5**.

Step 5:

Compound **5** (520 mg, 0.847 mmol) is cooled in an ice bath and treated with 4N HCl in dioxane (10 ml). The mixture is stirred in the ice bath for 2 hours and at ambient temperature (24°C) for 1.5 hours and concentrated. Three 4.0 ml portions of CH₂Cl₂ are mixed with the residue with concentration after each addition to give **6**.


Step 6:

A stirred mixture of **6** (400 mg, 0.727 mmol), triethylamine (0.81 ml, 5.82 mmol) and methyl dithiopropionate (350 mg, 2.91 mmol) in CH₂Cl₂ (7 ml)/THF (7 ml) is kept at ambient temperature (24°C) for 2 days, mixed with water and extracted with CH₂Cl₂. The extract is dried (MgSO₄) and concentrated. Chromatography of the residue on silica gel with 5% MeOH/0.5% NH₄OH/CH₂Cl₂ gave the product which is crystallized from CH₂Cl₂/heptane to give the titled product **7**.

MS (FAB) m/z 586 (M+H⁺); HRMS (FAB) calcd for C₂₉H₃₇FN₅O₅S (M+H⁺) 586.2499, found 586.2485. Anal. Calcd for C₂₉H₃₆FN₅O₅S: C, 59.47; H, 6.20; N, 11.96. Found: C, 59.04; H, 6.25; N, 11.83.


Example 2: (S)-N-[[3-[3-Fluoro-4-[4-[(hydroxy acetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-[(dimethylamino)methyl]benzoic acid ester (**11**)

Step 1:




5 A stirred solution of **3** (Example 1, Step 2) (1.80 g, 3.99 mmol) and triethylamine (0.83 ml, 5.99 mmol) in CH_2Cl_2 (24 ml) is treated, dropwise with a solution of 3-(chloromethyl)benzoyl chloride (980 mg, 5.18 mmol) in CH_2Cl_2 (10 ml) and kept at ambient temperature (24°C) for 18 hours and at reflux for 5 hours. Additional 3-(chloromethyl)benzoyl chloride (150 μl) and triethylamine (166 μl) are added and the mixture is refluxed for 18 hours, mixed with saturated aqueous NaHCO_3 and extracted with CH_2Cl_2 . The extract is dried (MgSO_4) and concentrated. Chromatography of the residue on silica gel with 2.5% $\text{MeOH}-\text{CH}_2\text{Cl}_2$ gave 1.68 g of **8**.


Step 2:



15 A stirred mixture of **8** (725 mg, 1.20 mmol), sodium iodide (12 mg), 2 M dimethylamine in MeOH (2.3 ml, 4.56 mmol) and acetone (16 ml) is kept at ambient temperature (24°C) for 4 days, mixed with water and extracted with CH_2Cl_2 . The extract is dried (MgSO_4) and concentrated. Chromatography of the residue on silica gel with mixtures of $\text{MeOH}/\text{CH}_2\text{Cl}_2$ containing 2.5-5% MeOH gave 632 mg of **9**.

Step 3:


Compound **9** (570 mg, 0.929 mmol) is cooled in an ice bath and treated with 4N HCl in dioxane (10 ml). The mixture is stirred in the ice bath for 2 hours and at ambient temperature (24°C) for 1.5 hours and concentrated. The residue is mixed with three 40 ml portions of CH₂Cl₂ with concentration after and each addition to give **10**.

Step 4:

A stirred mixture of **10** (490 mg, 0.891 mmol), triethylamine (0.99 ml, 7.13 mmol) and methyl dithiopropionate (429 mg, 3.56 mmol) in CH₂Cl₂ (8.5 ml)/THF (8.5 ml) is kept at ambient temperature (24°C) for 18 hours and concentrated. Chromatography of the residue on silica gel with 5% MeOH/CH₂Cl₂ gave a mixture of **11** and its hydrochloride salt. This is mixed with saturated aqueous NaHCO₃ and extracted with EtOAc. The extract is washed with dilute NaCl, dried (MgSO₄) and concentrated. Crystallization of the residue from EtOAc-heptane gave 329 mg of the titled product **11**.

Anal. Calcd for C₂₉H₃₆FN₅O₅S: C, 59.47; H, 6.20; N, 11.96. Found: C, 59.16; H, 6.30; N, 11.81.


Example 3: (S)-N-[[3-[3-Fluoro-4-[4-[(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-(morpholinomethyl)benzoic acid ester (**12**)



This compound is prepared as described for **11** in Example 2 by substituting morpholine for dimethylamine in Step 2 and refluxing the mixture for 4 days. The titled compound **12** is recrystallized from MeOH and had: MS (EI) m/z 627 (M^+).

Anal. Calcd for $C_{31}H_{38}FN_5O_6S$: C, 59.31; H, 6.10; N, 11.16. Found: C, 59.32; H, 6.18; N, 11.12.


Example 4: (*S*)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-[(4-methyl-1-piperazinyl)methyl]benzoic acid ester (**13**)



This compound is prepared as described for **11** in Example 2 by substituting 4-methylpiperazine for dimethylamine and CH_2Cl_2 for acetone in Step 2 and refluxing the mixture for 18 hours to give the titled product (**13**).

MS (EI) m/z 640 (M^+); HRMS (FAB) calcd for $C_{32}H_{42}FN_6O_5S$ ($M+H^+$) 641.2921, found: 641.2915.


Example 5: (*S*)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-[(diethylamino)methyl]benzoic acid ester (**14**)



This compound is prepared as described for **11** in Example 2 by substituting diethylamine for dimethylamine in Step 2 and refluxing the mixture for 18 hours. The titled product (**14**) is crystallized from acetone-heptane.

MS (EI) m/z 613 (M^+). Anal. Calcd for $C_{31}H_{40}FN_5O_5S$: C, 60.67; H, 6.57; N, 11.41. Found: C, 60.55; H, 6.62; N, 11.39.


Example 6: (*S*)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(diethylamino)methyl]benzoic acid ester (**15**)



Compound **15** is prepared as described for compound **7** in Example 1 by substituting diethylamine for dimethylamine in Step 4 and allowing the reaction to proceed for 2 days at ambient temperature and at reflux for 5 hours. The titled product (**15**) is crystallized from EtOAc-heptane.

MS (EI) m/z 613 (M^+). Anal. Calcd for $C_{31}H_{40}FN_5O_5S$: C, 60.67; H, 6.57; N, 11.41. Found: C, 60.61; H, 6.67; N, 11.32.


Example 7: (*S*)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-(morpholinomethyl)benzoic acid ester (**16**)



This compound is prepared as described for compound **7** in Example 1 by substituting morpholine for dimethylamine in Step 4 and refluxing the mixture for 24 hours. The titled product **16** is recrystallized from acetone- CH_2Cl_2 .

MS (EI) m/z 627 (M^+). Anal. Calcd for $C_{31}H_{38}FN_5O_6S$: C, 59.31; H, 6.10; N, 11.16. Found: C, 59.17; H, 6.21; N, 11.05.


Example 8: (*S*)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid ester (**17**)

**17**

This compound is prepared as described for compound **7** in Example 1 by substituting 1-methylpiperazine for dimethylamine and CH₂Cl₂ for acetone in Step 4 and refluxing the mixture for 24 hours. In Step 6 of this synthesis the product is mixed with saturated aqueous NaHCO₃ and extracted with EtOAc to give the pure free base **17**, which is recrystallized from acetone-heptane.

MS (EI) m/z 640 (M⁺); HRMS (FAB) calcd for C₃₂H₄₂FN₆O₅S (M+H⁺) 641.2921, found: 641.2916. Anal. Calcd for C₃₂H₄₁FN₆O₅S: C, 59.98, H, 6.45; N, 13.11. Found: C, 59.70; H, 6.53; N, 13.05.

Example 9: (*S*)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarbothioamide 4-[(dimethylamino)methyl]benzoic acid ester (**18**)




A stirred mixture of **6** (Example 1, Step 5) (792 mg, 1.44 mmol), triethylamine (1.6 ml, 11.5 mmol), ethyl dithiocyclopropanecarboxylate (842 mg, 5.76 mmol) and MeOH (20 ml) is kept at ambient temperature (24°C) for 2 hours and concentrated. The residue is triturated with EtOAc (15 ml) for 18 hours and the resulting solid is chromatographed on silica gel with 4% MeOH/CH₂Cl₂. The product is crystallized from EtOAc-heptane to give 388 mg of the title compound **18**.

MS (EI) m/z 597 (M^+); HRMS (FAB) calcd for $C_{30}H_{37}FN_5O_5S$ ($M+H^+$) 598.2499, found: 598.2510. Anal. Calcd for $C_{30}H_{36}FN_5O_5S$: C, 60.28; H, 6.07; N, 11.72. Found: C, 60.06; H, 6.14; N, 11.62.


- 5 **Example 10:** (*S*)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thiourea 4-[(dimethylamino)methyl]benzoic acid ester (**19**)

Step 1:




- 10 The hydrochloric acid salt (**6**) prepared from **5** (762 mg, 1.24 mmol) as in Example 1, Step 5 is neutralized with aqueous $NaHCO_3$ and extracted with CH_2Cl_2 . The extract is dried ($MgSO_4$) and concentrated to give 658 mg of **20**.

Step 2:




- 15 A stirred, ice cold solution of **20** (594 mg, 1.16 mmol) in CH_2Cl_2 (75 ml) is treated with 1,1'-thiocarbonyldi-2(1H)-pyridone (323 mg, 1.39 mmol), kept at ambient temperature ($24^\circ C$) for 18 hours and concentrated. Chromatography of the residue on silica gel with 2.5% MeOH/ CH_2Cl_2 gave a product mixture that is mixed with water and extracted with CH_2Cl_2 . The extract is washed with water, dried ($MgSO_4$) and concentrated to give 483 mg of **21**.

Step 3:


Excess anhydrous ammonia is bubbled into an ice cold solution of **21** (483 mg, 0.869 mmol) in THF (25 ml) and the mixture is stirred for 20 minutes and concentrated. Chromatography of the residue on silica gel with 10% MeOH/CH₂Cl₂ gave the title compound **19** which is recrystallized from acetonitrile.

MS (EI) *m/z* 572 (M⁺). Anal. Calcd for C₂₇H₃₃FN₆O₅S: C, 56.63; H, 5.81; N, 14.68. Found: C, 56.41; H, 5.89; N, 14.56.


- Example 11:** (*S*)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-(glycylamino)benzoic acid ester (**22**)

Step 1:

A stirred mixture of **3** (Example 1, Step 2) (1.098 g, 2.43 mmol) and triethylamine (0.70 ml) in CH₂Cl₂ (20 ml), under nitrogen is treated with 4-nitrobenzoyl chloride (0.553 g, 2.98 mmol) and kept at ambient temperature (24°C) for 3 hours. It is then treated with 1N HCl (10 ml) and extracted with CH₂Cl₂. The extract is dried (Na₂SO₄) and concentrated. Chromatography of the residue on silica gel with 2% MeOH/CH₂Cl₂ gave 1.24 g of **23**.


Step 2:

A mixture of **23** (1.24 g, 2.06 mmol), 10% palladium-on-carbon catalyst (0.51 g), MeOH (75 ml) and CH_2Cl_2 (75 ml) is hydrogenated at an initial pressure of 20 psi for 1 hour 50 minutes and filtered. Concentration of the filtrate gave 1.08 g of **24**.

Step 3:


An ice cold, stirred mixture of **24** (0.56 g, 0.98 mmol) and diisopropylethylamine (0.17 ml, 0.96 mmol) in THF (20 ml) under nitrogen is treated portionwise during 80 seconds with N-Fmoc-glycyl chloride (0.336 g, 1.06 mmol) and kept in the ice bath for 1 hour. Additional diisopropylethylamine (9 μ l) and N-Fmoc-glycyl chloride (0.04 g) are added and the reaction is continued for 65 minutes. The mixture is concentrated *in vacuo* and the residue is chromatographed on silica gel with 3% MeOH/ CH_2Cl_2 to give 0.80 g of **25**.

Step 4:




An ice cold solution of **25** (0.23 g, 0.27 mmol) in dioxane (6 ml), under nitrogen, is treated, dropwise with cold 4N HCl in dioxane (3 ml), kept in the ice bath for 100 minutes and at ambient temperature for 2 hours and concentrated *in vacuo* to give 0.31 g of **26**.

Step 5:



A stirred mixture of **26** (0.20 g), diisopropylethylamine (0.26 ml), THF (6 ml) and CH_2Cl_2 (25 ml) is treated with ethyl dithiopropionate (0.10 ml) and kept at ambient temperature (24°C) for 26 hours. Methanol (5 ml) is added to the mixture which is kept at ambient temperature for 48 hours and at 45-50°C for 4 hours. It is concentrated and the residue is chromatographed over silica gel with 2.5% MeOH/ CH_2Cl_2 to give 0.09 g of **27**.

Step 6:




A stirred solution of **27** (0.09 g) in DMF (1 ml), under nitrogen, is treated with piperidine (0.027 ml), kept at ambient temperature for 15 min and concentrated *in vacuo*.

- 5 Chromatography of the residue on silica gel with 0.4% NH_4OH /4% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ gave the title compound **22**.

HRMS (FAB) calcd for $\text{C}_{28}\text{H}_{34}\text{FN}_6\text{O}_6\text{S}$ ($\text{M}+\text{H}^+$) 601.2244, found 601.2251.


- Example 12:** (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarbothioamide 4-(glycylamino)benzoic acid ester (**28**)
- 10




- The title compound **28** is prepared as described for compound **22** in Example 11 by substituting ethyl dithiocyclopropanecarboxylate for ethyl dithiopropionate in Step 5 which is carried out in MeOH at 45°C.
- 15

HRMS (FAB) calcd for $\text{C}_{29}\text{H}_{34}\text{FN}_6\text{O}_6\text{S}$ ($\text{M}+\text{H}^+$) 613.2244, found 613.2233.


Example 13: (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-(L-alanyl)benzoic acid ester (**29**)

Step 1:


A stirred mixture of carbobenzyloxy-L-alanine (0.48 g, 0.0022 mol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 0.43 g, 0.0023 mol) in pyridine (15 ml) was kept, under nitrogen, for 5 minutes and treated with 4-(dimethylamino)pyridine (15 mg) and **24** (Example **11**, Step 2) (1.0 g, 0.0018 mol). The mixture was kept at ambient temperature (24°C) for 21 hours, treated with additional carbobenzyloxy-L-alanine (0.20 g) and EDC (0.18 g), kept at ambient temperature for 6 hours and at 0°C for 72 hours and concentrated *in vacuo*. Chromatography of the residue on silica gel with 2.5% MeOH-CHCl₃ gave 1.1 g of **30**: MS (ES) *m/z* 777 (M+H⁺), 799 (M+Na⁺)

Step 2:

An ice cooled, stirred mixture of **30** (1.1 g) and dioxane (20 ml), under nitrogen, was treated during 3 minutes with ice cold 4N hydrogen chloride in dioxane (10 ml) and kept in the ice bath for 1 hour and at ambient temperature for 2 hours and 20 minutes. Excess hydrogen chloride was removed under a stream of nitrogen and the remaining mixture was concentrated *in vacuo* to give 1.1 g of **31**, a white solid: MS (ES) *m/z* 677 (M+H⁺).

Step 3:

- 5 A stirred mixture of **31** (0.5 g) and triethylamine (0.36 ml) in methanol (10 ml) under nitrogen, was treated with ethyl dithiopropionate (0.10 ml) and kept at ambient temperature for 1 hour 45 minutes. The solid was collected by filtration and washed with cold MeOH to give 0.26 g of **32**, a white solid: MS (ES) m/z 749 ($\text{M}+\text{H}^+$).


Step 4:

- 10 Compound **32** (0.13 g) was treated with 30% hydrogen bromide in acetic acid (3.8 ml) stirred at ambient temperature for 30 minutes and mixed with Et_2O (25 ml). The supernatant liquid was decanted and the residue was washed twice with Et_2O and collected by filtration. A solution of the solid in water was neutralized (pH 9-10) with saturated aqueous NaHCO_3 and the resultant solid was collected by filtration and washed with water
- 15 to give 0.073 g of product. It was combined with the product (0.097g) from a second identical reaction and chromatographed on silica gel with 4% MeOH-0.2% NH_4OH - CH_2Cl_2 . Crystallization of the resulting product from MeOH gave 0.071 g of **29**: mp 220-221°C. HRMS (FAB) calcd for $\text{C}_{29}\text{H}_{36}\text{FN}_6\text{O}_6\text{S}$ ($\text{M}+\text{H}^+$) 615.2401, found 615.2405.

CLAIMS

We claim:

1. A compound of formula I:




5

I

or a pharmaceutically acceptable salt thereof wherein:

A is a structure i, ii, or iii



W is

- 10 a) $\text{NHC}(=\text{X})\text{R}_1$,
 b) -O-het, -S-het, or -NH-het; provided that when A is a structure iv, W is not the section b);



X is O, or S;

R₁ is

- 15 (a) H,
 (b) NH_2 ,
 (c) $\text{NHC}_{1-4}\text{alkyl}$,
 (d) $\text{C}_{1-4}\text{alkyl}$, optionally substituted by one or more F, Cl, or CN,
 (e) $\text{C}_{2-4}\text{alkenyl}$,
 (f) $\text{OC}_{1-4}\text{alkyl}$,
 (g) $\text{SC}_{1-4}\text{alkyl}$, or
 (h) $(\text{CH}_2)_n\text{C}_{3-6}\text{cycloalkyl}$;
- 20

R₂ and R₃ are independently H, F, Cl or C₁₋₂alkyl;

R₄ is positioned at either C-3 or C-4 and is:




R₅ is H, or CH₃;

R₆ is H, or C₁₋₄alkyl, optionally substituted by OH, SH, SCH₃, NH₂ or NHC(=NH)NH₂;

R₇ and R₈ are independently

- 5 (a) H,
- (b) C₁₋₄alkyl, or
- (c) R₇ and R₈ together with the nitrogen to which they are attached to form a saturated 5-, 6-, or 7-membered heterocyclic ring which may have additional heteroatoms selected from the group consisting of O, S(O)_n, or N-R₅;
- 10 het is a C-linked five- (5) or six- (6) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring; at each occurrence, wherein het is optionally substituted with one or more halo, OH, CF₃, OC₁₋₆alkyl, CN, C₁₋₆ alkyl, S(=O)_iR⁹, C(=X)R¹⁰, OC(=O)R¹⁰, NHC(=O)R¹⁰, or NR¹⁰R¹⁰, oxo, or oxime; wherein R⁹ is
- 15 C₁₋₆alkyl, aryl, or NR⁷R⁸; R¹⁰ is H, C₁₋₆alkyl, aryl, or NR⁷R⁸;
- n is 0, 1, or 2; and with the proviso that when X is O, R₄ is not the subsection (a).

2. A compound of claim 1 which is a compound of formula IA




IA.

3. A compound of claim 2 wherein R₁ is C₁₋₄alkyl.
4. A compound of claim 2 wherein R₁ is ethyl.
5. A compound of claim 2 wherein R₁ is NH₂.

6. A compound of claim 2 wherein R₁ is C₃₋₆cycloalkyl.
7. A compound of claim 1 wherein X is sulfur atom.
- 5 8. A compound of claim 1 wherein X oxygen atom.
9. A compound of claim 1 wherein R₂ and R₃ are independently H or F.
- 10 10. A compound of formula I according to claim 1 wherein at least one of said R₂ and R₃ is H, the other one is F.
11. A compound of claim 1 wherein R₄ is -CH₂N(CH₃)₂.
- 15 12. A compound of claim 1 wherein R₄ is 4-morpholinylmethyl.
13. A compound of claim 1 wherein R₄ is 4-methyl-1-piperazinylmethyl.
14. A compound of claim 1 wherein R₄ is
- $$\begin{array}{c} \text{R}_5 \\ | \\ -\text{CH}-\text{N} \begin{array}{l} \nearrow \text{R}_7 \\ \searrow \text{R}_8 \end{array} \end{array}$$
- 20 wherein R₅, R₇ and R₈ are the same as defined in claim 1.
15. Use of a compound of formula I as shown in Claim 1, for manufacturing of medicinals for treating microbial infections.
- 25 16. The use of claim 15 wherein said compound of formula I is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.
17. The use of claim 15 wherein said compound is administered in an amount of from
- 30 about 0.1 to about 100 mg/kg of body weight/day.

18. The use of claim 15 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.
19. A use for treating microbial infections of claim 15 wherein the infection is skin infection.
20. A use for treating microbial infections of claim 15 wherein the infection is eye infection.
21. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
22. A compound of claim 1 which is
- (1) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(dimethylamino)methyl]benzoic acid ester,
- (2) (S)-N-[[3-[3-fluoro-4-[4-[(hydroxy acetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-[(dimethylamino)methyl]benzoic acid ester,
- (3) (S)-N-[[3-[3-fluoro-4-[4-[(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-(morpholinomethyl)benzoic acid ester,
- (4) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-[(4-methyl-1-piperazinyl)methyl]benzoic acid ester,
- (5) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 3-[(diethylamino)methyl]benzoic acid ester,
- (6) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(diethylamino)methyl]benzoic acid ester,
- (7) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-(morpholinomethyl)benzoic acid ester,
- (8) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid ester,

- (9) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarbothioamide 4-[(dimethylamino)methyl]benzoic acid ester,
- (10) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thiourea 4-[(dimethylamino)methyl]benzoic acid ester,
- (11) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-(glycylamino)benzoic acid ester,
- (12) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarbothioamide 4-(glycylamino)benzoic acid ester, or
- (13) (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-(L-alanyl amino)benzoic acid ester.
23. A compound of claim 1 which is
- (1) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(dimethylamino)methyl]benzoic acid ester,
- (2) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-(morpholinomethyl)benzoic acid ester, or
- (3) (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]propanethioamide 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid ester.
24. A compound of claim 1 wherein structure i, or iii is



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/32432

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D263/20 A61K31/495 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 652 238 A (BRICKNER ET. AL.) 29 July 1997 (1997-07-29) cited in the application claims; examples 7,8,21,28 ---	1-24
Y	WO 97 30981 A (PHARMACIA AND UPJOHN) 28 August 1997 (1997-08-28) claims; examples ---	1-24
P, Y	WO 99 64416 A (ZENECA) 16 December 1999 (1999-12-16) claims; examples -----	1-24

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

14 February 2001

Date of mailing of the international search report

21/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Helps, I

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/32432

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5652238 A	29-07-1997	AT 182142 T	15-07-1999
		AU 698699 B	05-11-1998
		AU 8010394 A	13-06-1995
		CA 2174107 A	01-06-1995
		CN 1135752 A, B	13-11-1996
		DE 69419523 D	19-08-1999
		DE 69419523 T	25-11-1999
		DK 730591 T	31-01-2000
		EP 0730591 A	11-09-1996
		ES 2133588 T	16-09-1999
		GR 3031420 T	31-01-2000
		JP 9505582 T	03-06-1997
		LV 12538 A	20-10-2000
		NZ 274966 A	26-01-1998
		SI 730591 T	31-12-1999
		WO 9514684 A	01-06-1995
		ZA 9407885 A	09-04-1996
WO 9730981 A	28-08-1997	AU 703831 B	01-04-1999
		AU 1954797 A	10-09-1997
		CA 2243706 A	28-08-1997
		EP 0883611 A	16-12-1998
		JP 2000505084 T	25-04-2000
		US 5736545 A	07-04-1998
		ZA 9701287 A	14-08-1998
WO 9964416 A	16-12-1999	AU 4156599 A	30-12-1999